CMP Therapeutics Ltd.
This article was originally published in Start Up
Executive Summary
Chitin may be the second most common molecule on earth. It could be the source of a treatment for the common cold, too. So hope investors in CMP Therapeutics Ltd., which is developing a micronized nose-spray version of the polysaccharide chitin. The company is also using chitin as the basis for programs in novel allergy and asthma therapies, vaccine adjuvants, and nutritional products.
You may also be interested in...
Start-Up Previews (07/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Alzheimer's Start-Ups Face A Discovery And Clinical Crossroads," features profiles of AlzProtect, Axerion Therapeutics, Cognition Therapeutics and Galantos Pharma. "The Future of Laparoscopy: Single Incision, NOTES And Robots," features profiles of EndoControl, Ovesco Endoscopy, SurgiQuest and Virtual Incision. Plus these Start-Ups Across Health Care: Antabio, Beta-Stim, CMP Therapeutics, Elixir Medical, Kerecis, Optivia Biotechnology, Quanterix and reinnervate.
With A New CSO, Bristol-Myers Squibb Doubles Down On Immuno-Oncology
BMS’ strategy for the complex, highly competitive immuno-oncology field. A Q&A with the company’s new R&D chief, lung cancer specialist Thomas Lynch, MD.